Floatz logo

Zeprumetostat

Adult Brain Glioblastoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Adult Brain Glioblastoma cohort.

Asset / SponsorPhaseRating
Polyiclc
University Hospital, Geneva
Phase 1/2CCC
CARMUSTINE
Leland Metheny
Phase 2CCC
Fuzuloparib
National Cancer Institute (NCI)
Phase 2CCC
trc102
National Cancer Institute (NCI)
Phase 2CCC
Gm-Csf
Stemline Therapeutics, Inc.
Phase 1/2CCC

View all 12 →

Same molecule, other indications

Zeprumetostat is also rated in:

Chronic Postsurgical PainDormant
B
Indicative ·
60 / 100
View asset →
Obese Patients With Prostate Cancer DiseaseDormant
B
Indicative ·
60 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →